MAXHEALTH:NSEMAXHEALTH FUTURES Analysis

The stock is trading at ₹1,012.45, comfortably above its 20‑day SMA of ₹1,005.15 and 50‑day SMA of ₹999.77, yet still below the 200‑day SMA of ₹1,067.79, indicating a short‑term upside bias within a longer‑term downtrend. RSI sits at 53.6, suggesting neutral momentum, while the MACD histogram is positive (+3.06) and the MACD signal is bullish, pointing to emerging price strength. Support sits at ₹919.80 and resistance at ₹1,111, framing a ~₹190 range, and the current price is roughly midway, offering a balanced risk‑reward profile. Volume has been decreasing, trading at 760,161 against a 10‑day average of 4,181,955, which could constrain short‑term liquidity, but the low beta (‑0.25) implies minimal market‑wide volatility exposure. The Fear & Greed Index reads 89.86 (Extreme Greed), reflecting strong market optimism despite a 30‑day volatility of 30.2% and a historical max drawdown of 28.4%.
Given a forward P/E of 41.73 versus a trailing P/E of 68.69, earnings expectations are improving, though the price‑to‑book ratio of 9.16 and modest dividend yield of 0.15% suggest the stock is priced for growth rather than income. The neutral trend direction combined with bullish technical cues and a solid market‑cap of ₹985.36 bn positions MAXHEALTH as a candidate for steady accumulation, provided investors monitor volume trends and the proximity to the identified support level.